Welcome to the December 2011 edition of Current Agreements Deals Update.
This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in November 2011.
Deal of the month
Acquisition agreement for Pharmasset
Gilead, Pharmasset - November 21, 2011
Definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash more
Breaking news...
Joint venture, development, manufacturing and marketing agreement for biosimilars
Biogen Idec, Samsung - December 5, 2011
Asset purchase and licensing agreement for Sialic Switch assets
Momenta, Virdante - December 5, 2011
For more breaking deals as they are announced, visit: http://www.currentagreements.com
What's new...
Between now and end of December 2011, we are offering a 10% discount off subscriptions to Current Agreements.
To benefit from the discount, simply quote Xmas2011 when ordering from our online store.
You can also use the same offer on all our report titles - see the full list at the Current Partnering report store. Simply use the coupon code Xmas2011 at checkout.
Month In Review
Welcome to the December 2011 edition of Current Agreements Deals Update.
This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in November 2011.
As we move into winter, partnering activity appears to continue at a good pace. A total of 283 partnering deals were announced during the month, with the top deal by value being the co-development and co-promotion agreement for psychiatric and neuroscience drugs between Lundbeck and Otsuka. The deal had a headline value of USD1.8 billion. Further details can be viewed here.
M&A also saw significant activity with 37 deals announced, with the leading deal being the acquisition of Pharmasset by Gilead for USD11 billion. Full details including contract here.
Our sister company, Current Partnering has just published two new reports:
In addition, with the emerging role of personalized medicine in recent dealmaking we have published a series of reports:
- Personalized Medicine Partnering Terms and Agreements
- Biomarker Partnering Terms and Agreements
- Companion Diagnostics Partnering Terms and Agreements
- Pharmacogenomic Partnering Terms and Agreements
All our reports are currently available with a 10% discount until the end of December 2011 - simply quote the coupon code Xmas2011 at checkout.
Our newly launched Current Partnering website showcases the leading partnering, M&A and financing deals by value.
To see the leading deals of 2011 so far, view the set of Scorecards for 2011: Top partnering deals 2011 | Top M&A deals 2011 - check them out.
We have also recenly updated our highly popular Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report - further details here.
We welcome your comments and feedback on this newsletter. We also welcome contact from any company that has a deal not already announced by press release, allowing us to add non-publicized deals to the database.
Regards
Steve Poile
The Top Ten
The following are the top 10 partnering deals and alliances by value, as announced in November 2011.
1. Co-development and co-promotion agreement for up to five innovative psychiatric and neuroscience products - Otsuka, Lundbeck - USD1800m
2. Termination agreement for Bydureon (exenatide) once-weekly - Elil Lilly, Amylin - USD1600m
3. Licensing agreement for Spinal Muscular Atrophy (SMA) programme - Roche, PTC Therapeutics - USD490m
4. Asset purchase agreement for Graceway assets - Medicis, Graceway Pharmaceuticals - USD455m
5. Development, manufacturing, marketing and licensing agreement for AKT inhibitor ARQ 092 - Daiichi Sankyo, ArQule - USD265m
6. Licensing option agreement for several pre-defined pathogens - Sanofi-Pasteur, CureVac - USD203.5m
7. Grant award for $117 million for Texas cancer research and drug development projects - Cancer Prevention and Research Institute of Texas - USD117m
8. Licensing and distribution agreement for Travelan - Paladin Labs, Immuron - USD112.93m
9. Asset purchase agreement for Treo plus two additional OTC products - Cilag, McNeil Consumer Pharmaceuticals, Meda - USD111m
10. Asset purchase agreement for generic business assets - Stada, Spirig Pharma - USD107m
Full details of each deal available at Current Agreements*
*Subscription required
Bigpharma Partnering
November saw 46 partnering deals announced where bigpharma were at least one of the parties to the deal. This is down from the 53 deals recorded in the previous month.
Two companies led partnering activity in November:
- Johnson & Johnson - signed deals with Gilead (via Tibotec), International Mentail Health Research Organisation (via Janssen), Furiex Pharma (via Janssen), Affymax (via Jannsen Biotech)
- Roche - signed deals with PTC Therapeutics, Axolabs, Cedars-Sinai Medical Center, Galena Biopharma/Henry M Jackson Foundation
Further details are available at Current Agreements.
Deal Update Articles
Recent deals and alliances in life sciences - here's our take:
Who’s next in the hepatitis C acquisition trail?
The recent acquisition of Pharmasset for a record breaking drug maker acquisition by Gilead has got markets asking who will be next more
Valeant continues acquisition trail by snagging iNova
In the latest of a number of acquisitions this year, Valeant has announced its latest acquisition – iNova Pharmaceuticals more
Gilead acquires Pharmasset in $11 billion mega bet on interferon-free drugs
Gilead has acquired Pharmasset for a massive $11 billion, in one of the biggest acquisition deals of 2011
Lundbeck and Otsuka ink blockbuster CNS deal
In one of the largest partnering deals of the year, Lundbeck and Otsuka have entered into a long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide
